Inhibikase Therapeutics Inc Stock Price, News & Analysis

Inhibikase Therapeutics (Nasdaq: IKT) will disclose its financial results for the full year ended December 31, 2021, on March 31, 2022. The announcement will be followed by a conference call and webcast on April 1, 2022, at 8:00 a.m. ET, where the company will provide a corporate update. Inhibikase is focused on developing therapeutics aimed at modifying the course of Parkinson's disease and related disorders, with its lead program targeting the disease both in the brain and gastrointestinal tract.

Inhibikase Therapeutics (Nasdaq: IKT), a clinical-stage pharmaceutical firm focusing on Parkinson's disease, announced that Dr. Milton Werner will present at the Maxim Group 2022 Virtual Growth Conference from March 28 to 30. The presentation will be available for on-demand viewing starting March 28 at 9:00 AM ET on the company's website. Inhibikase is advancing therapeutics targeting neurodegenerative disorders, including its leading program IkT-148009, aimed at treating Parkinson's disease and related conditions.

Inhibikase Therapeutics (Nasdaq: IKT) announced that Dr. Milton Werner will present at the AD/PD™ Conference in Barcelona from March 15-20, 2022. The presentation will cover results from preclinical and Phase 1 studies of IkT-148009, a selective Abelson Tyrosine Kinase inhibitor for Parkinson's disease. Results indicate IkT-148009 clears alpha-synuclein aggregates, protects neurons, and shows no significant adverse events across 88 subjects. The company plans to initiate a Phase 2 study in Q2 2022, further validating the therapeutic potential of IkT-148009 as a disease-modifying treatment.

Inhibikase Therapeutics (Nasdaq: IKT) reported significant milestones and goals for 2022, focusing on Parkinson's disease therapies, particularly IkT-148009. Key developments include continuing Phase 1 dosing studies in healthy volunteers and patients, completing chronic toxicology data submissions to the FDA, and initiating Phase 2a clinical studies for IkT-148009. The company also aims to advance IkT-001Pro for Chronic Myelogenous Leukemia. Inhibikase's President highlighted the transformative year of 2021 and expressed optimism for 2022's advancements in treating neurodegenerative diseases.

Inhibikase Therapeutics (Nasdaq: IKT) announced a new publication detailing the role of Abelson Tyrosine Kinase (c-Abl) inhibition in treating Parkinson's disease. The paper, published on November 24, 2021, highlights the disease-modifying potential of IkT-148009, a selective c-Abl kinase inhibitor. Preclinical studies indicate that this therapy can clear alpha-synuclein aggregates and promote neuron regeneration. Currently, IkT-148009 is in a Phase 1b trial to assess safety and efficacy, with results expected in 2022.

Inhibikase Therapeutics (Nasdaq: IKT) reported its Q3 2021 financial results, highlighting a net loss of $4.5 million, or $0.18 per share, compared to a loss of $0.7 million in Q3 2020. The company dosed its first patient in the Phase 1b trial of IkT-148009 for Parkinson's disease, which aims to assess safety and tolerability. Additionally, they expanded the trial to higher doses and submitted interim toxicology data to the FDA. Inhibikase also received a grant from the NIH to study IkT-148009 for Multiple System Atrophy.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced that Dr. Milton Werner, CEO, will participate in the Michael J. Fox Foundation Alpha-Synuclein Summit on November 3-4, 2021. Dr. Werner will present on the role of c-Abl in neurodegeneration and neuroinflammation in Parkinson's disease and share data on IkT-148009, a c-Abl inhibitor, showcasing its potential as a treatment option. His presentation will be followed by a panel discussion on strategies to address alpha-synuclein pathology in patients.

Inhibikase Therapeutics (Nasdaq: IKT) announced the dosing of the first patient in its Phase 1b clinical trial for IkT-148009, a c-Abl inhibitor targeting Parkinson's disease. The randomized, placebo-controlled study will enroll 24 patients to evaluate safety, tolerability, and pharmacokinetics. Previous Phase 1 results indicated no significant adverse events in 56 healthy volunteers. The c-Abl target may help restore neuron function and mitigate disease effects. Inhibikase aims to progress to a Phase 2a study in 2022, pending Phase 1b outcomes.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced interim three-month results from chronic toxicology studies for its oral drug IkT-148009, aimed at treating Parkinson's disease. The studies, involving rats and non-human primates, revealed an improved toxicology profile with increased NOAEL measurements, suggesting enhanced safety with prolonged dosing. Following FDA review of these results, Inhibikase plans to initiate a Phase 2a study in 2022, evaluating IkT-148009's effects on up to 120 Parkinson's patients. The selective c-Abl kinase inhibitor demonstrates promising potential for better safety and tolerability.